ADRs traded lower on Tuesday after Bernstein downgraded the Danish biotech to Underperform from Market Perform, arguing that ...

Bernstein downgraded Genmab (GMAB) to Underperform from Market Perform with a price target of DKK 1,000, down from DKK 1,580. The share price ...

Bernstein analyst Justin Smith downgraded Genmab A/S (0MGB – Research Report) to a Sell on March 28 and set a price target of DKK1,000.00. The ...

Investing.com -- Bernstein analysts have downgraded Genmab A/S (CSE: GMAB) to an "underperform" rating from "market perform,” in a note dated Tuesday. Shares of the Danish biotechnology company were ...

A multibillion-dollar partnership between AbbVie and Genmab risks being soured by a lawsuit claiming misappropriation of trade secrets. Specifically, it focuses on the use of disaccharides to ...

AbbVie has filed a lawsuit against Genmab, accusing the Danish drugmaker of being “intentionally and willfully blind” to the theft of trade secrets. Genmab has vowed to “vigorously defend ...

Envestnet Portfolio Solutions Inc. reduced its holdings in Genmab A/S (NASDAQ:GMAB – Free Report) by 29.3% in the 4th quarter, according to the company in its most recent 13F filing with the ...

Equities researchers at William Blair issued their Q1 2026 earnings per share (EPS) estimates for Genmab A/S in a research note issued on Tuesday, March 18th. William Blair analyst M. Phipps ...

COPENHAGEN, Denmark; March 22, 2025 – Genmab A/S (Nasdaq: GMAB) announced today thatAbbVie Inc. (AbbVie) has filed a complaint in the U.S. District Court for the Western District of Washington ...

COPENHAGEN, Monday - Genmab A/S (NASDAQ:GMAB), a global biotechnology company specializing in antibody therapeutics with a market capitalization of $12.35 billion, has announced a series of ...

Also Read: AbbVie/Genmab’s Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway The trial included 502 patients, 101 of which were Japanese.

COPENHAGEN, Monday - Genmab (CSE:GMAB) A/S (NASDAQ:GMAB), a global biotechnology company specializing in antibody therapeutics with a market capitalization of $12.35 billion, has announced a series of ...